Version history

{
  "session_id": "sess_SDA-2026-04-04-gap-neuroinflammation-microglial-20260404_20260412-074848",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "synthesize",
  "content": "\n\n{\n  \"ranked_hypotheses\": [\n    {\n      \"rank\": 1,\n      \"title\": \"TREM2/APOE4-Modulated Metabolic Reprogramming Drives Inflammatory Microglial Priming\",\n      \"mechanism\": \"APOE4 and TREM2 R47H impair microglial metabolic flexibility by disrupting PI3K/AKT signaling and glycolytic adaptation, locking cells into a pro-inflammatory state characterized by glycolysis addiction, mitochondrial dysfunction, and heightened DAMPs responsiveness during prodromal AD.\",\n      \"target_gene\": \"TREM2/APOE\",\n      \"confidence_score\": 0.78,\n      \"novelty_score\": 0.55,\n      \"feasibility_score\": 0.72,\n      \"impact_score\": 0.75,\n      \"composite_score\": 0.72,\n      \"testable_prediction\": \"Single-cell RNA-seq of TREM2 R47H iPSC-derived microglia exposed to peripheral cytokines will show glycolytic gene upregulation and impaired oxidative phosphorylation gene programs compared to wild-type controls.\",\n      \"skeptic_concern\": \"Metabolic changes may be secondary effects of activation rather than causative drivers of priming.\"\n    },\n    {\n      \"rank\": 2,\n      \"title\": \"DAMPs/PRR Signaling Threshold Lowering Establishes Microglial Inflammatory Memory\",\n      \"mechanism\": \"Chronic peripheral inflammation generates circulating DAMPs (HMGB1, ATP, mtDNA) that continuously engage microglial PRRs (TLR4, TLR9, P2X7R), progressively lowering activation thresholds so that subthreshold Aβ aggregates trigger exaggerated TNFα/IL1β responses in prodromal phases.\",\n      \"target_gene\": \"HMGB1/TLR4/P2X7R\",\n      \"confidence_score\": 0.70,\n      \"novelty_score\": 0.65,\n      \"feasibility_score\": 0.65,\n      \"impact_score\": 0.72,\n      \"composite_score\": 0.69,\n      \"testable_prediction\": \"Peripheral LPS pretreatment in 5xFAD mice will result in increased HMGB1-TLR4 colocalization in hippocampal microglia and exaggerated cytokine surges upon subthreshold Aβ challenge compared to vehicle-pretreated controls.\",\n      \"skeptic_concern\": \"DAMPs may represent biomarkers of existing pathology rather than causal priming mechanisms.\"\n    },\n    {\n      \"rank\": 3,\n      \"title\": \"PRC2/EZH2 Epigenetic Lock-In Perpetuates Peripheral Inflammation Memory in Microglia\",\n      \"mechanism\": \"Sustained peripheral inflammaging causes NF-κB p65-mediated EZH2 downregulation, depleting repressive H3K27me3 marks at pro-inflammatory gene loci and creating transcriptionally unlocked promoters that mount hypersensitive responses to CNS-derived subthreshold stimuli.\",\n      \"target_gene\": \"EZH2\",\n      \"confidence_score\": 0.58,\n      \"novelty_score\": 0.75,\n      \"feasibility_score\": 0.40,\n      \"impact_score\": 0.78,\n      \"composite_score\": 0.64,\n      \"testable_prediction\": \"ChIP-seq comparing H3K27me3 enrichment at IL1β, TNFα, and CCL2 promoters in aged APOE4 vs. APOE3 microglia will reveal significant mark depletion correlated with LPS hyperresponsiveness.\",\n      \"skeptic_concern\": \"EZH2 loss may be a consequence of activation rather than its cause, and selective pharmacological restoration of EZH2 in microglia without oncological risk remains technically challenging.\"\n    }\n  ],\n  \"consensus_points\": [\n    \"Microglial priming represents a critical early mechanism in AD pathophysiology preceding frank pathology\",\n    \"Genetic risk factors (APOE4, TREM2 R47H) and peripheral inflammation converge on shared microglial activation pathways\",\n    \"The prodromal phase offers a therapeutic window where microglial reprogramming could modify disease trajectory\"\n  ],\n  \"dissent_points\": [\n    \"Whether microglial metabolic/epigenetic changes are causative drivers of priming or merely epiphenomena of activation state remains unresolved\"\n  ],\n  \"debate_summary\": \"The debate converges on microglial priming as a central early AD mechanism where peripheral inflammation, aging, and genetic risk factors synergistically drive pathological activation states. While the TREM2/APOE-metabolic axis received the highest composite score due to superior experimental tractability and established mechanistic foundations, the epigenetic PRC2/EZH2 hypothesis offers the greatest theoretical novelty despite facing significant pharmacological feasibility concerns. DAMPs/PRR signaling represents a mediating mechanism with moderate support across all perspectives.\"\n}",
  "tokens_used": "1062"
}